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Abstract: The endocannabinoid system (ECS) is a group of neuromodulatory lipids and their receptors, which are 
widely distributed in mammalian tissues. ECS regulates various cardiovascular, nervous, and immune system func-
tions inside cells. In recent years, there has been a growing body of evidence for the use of synthetic and natural 
cannabinoids as potential anticancer agents. For instance, the CB1 and CB2 receptors are assumed to play an impor-
tant role inside the endocannabinoid system. These receptors are abundantly expressed in the brain and fatty tissue 
of the human body. Despite recent developments in molecular biology, there is still a lack of knowledge about the 
distribution of CB1 and CB2 receptors in the human kidney and their role in kidney cancer. To address this gap, we 
explore and demonstrate the role of the endocannabinoid system in renal cell carcinoma (RCC). In this brief overview, we elucidate the 
therapeutic aspects of the endocannabinoid system for various cancers and explain how this system can be used for treating kidney can-
cer. Overall, this review provides new insights into cannabinoids’ mechanisms of action in both in vivo and in vitro models, and focuses 
on recent discoveries in the field.  
Keywords: CB1 and CB2 receptors, Cannabinoids, Endocannabinoid system, Renal cell carcinoma. 
INTRODUCTION 
 Extracts from Cannabis sativa L. have been used for both me-
dicinal and recreational purposes for many centuries. Cannabinoids 
are involved in a variety of physiological and pathological condi-
tions, including inflammation, immunomodulation, analgesia, and 
cancer [1]. Nevertheless, the most active component of the plant, 

9
-tetrahydrocannabinol (THC), began to be explored in 1960 [2]. 
There are approximately 66 unique compounds, known as cannabi-
noids, derived from Cannabis sativa L. [3]. Cannabinoids are clas-
sified into three categories: phytocannabinoids, which occur 
uniquely in the Cannabis sativa L. plant (i.e., THC, CBD [can-
nabidiol], and CBN [cannabinol]); endogenous cannabinoids, which 
are produced in the human body and those of other animals (i.e., 
anandamide and 2-arachidonoyl-glycerol); and synthetic cannabi-
noids, which are produced in laboratory conditions (i.e., JWH-133, 
WIN 55,212-2, and SR141716).  
 Initially, it was believed that cannabinoids, which are highly 
hydrophobic, mediate their action by binding directly to biomem-
brane proteins. However, the first cloning of cannabinoid receptors 
from the mammalian brain in 1990 led to the discovery of the basic 
mechanism of cannabinoid action [4]. At this point, cannabinoid 
research expanded to the study of cannanioids’ therapeutic effects. 
Currently, two cannabinoid receptor subtypes have been identified: 
cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 
(CB2). Both subtypes belong to the G-protein coupled receptor 
superfamily, which is responsible for the transduction of intercellu-
lar signals. The CB1 receptor is abundant in the brain and is also 
present in other tissues and organs of the body. Therefore, it is be-
lieved that the psychoactivity induced by cannabinoids is mostly 
regulated by CB1 receptors. In contrast to CB1, CB2 receptors are 
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expressed exclusively in immune system cells, including B and T 
lymphocytes and macrophages [5]. Activation of CB1 receptors 
stimulates cell signaling through Gi and Go activation, while on the 
other hand, CB2 increases signaling only with Gi [6]. The activation 
of these G-protein-coupled and cannabinoid receptors inhibits the 
enzymatic activity of adenylate cyclase, which is responsible for the 
production of cyclic adenosine monophosphate (cAMP) inside cells 
[1]. However, the underlying mechanisms through which cannabi-
noids and cannabinoid receptors inhibit proliferation and migration, 
and induce apoptosis of cancer cells, remain obscure. 
CANNABINOIDS IN CANCER TREATMENT: CHEMICAL 
APPROACHES TO THEIR SYNTHESIS 
 Cannabinoids are a family of compounds belonging to different 
chemical classes that can act on cannabinoid receptors (CB1 and 
CB2). They are grouped into three main classes: phytocannabinoids, 
which are naturally found in Cannabis sativa L. and other plants; 
endocannabinoids, which are naturally produced by mammalian 
species as endogenous CB1 and CB2 receptor agonists; and syn-
thetic cannabinoids, which produced under laboratory conditions. 
Recent studies provide lines of evidence that cannabinoids, in addi-
tion to well-known pharmacological activities as an antiemetic and 
in the treatment of glaucoma, exhibit anticancer and antiangiogenic 
properties. 
Phytocannabinoids  
 Phytocannabinoids are well-known natural products that are 
extracted and isolated from the Cannabis sativa L. plant (com-
monly known as marijuana). Marijuana has long been known for its 
medicinal and recreational properties. In 1964, Raphael Mechoulam 
and coworkers isolated one of the most active compounds from 
Cannabis sativa L., 
9
-tethrahydrocannabinol (
9
-THC) [2]. They 
were the first to chemically synthesize this compound, which made 
possible further biological studies that confirmed 
9
-THC as its 
major active compound [7]. Since then, 60 unique phytocannabi-
noids, such as cannabidiol (CBD), cannabinol (CBN), and cannibi-
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gerol (CBG), together with endogenous cannabinoids, such as anan-
damide (arachidonoylethanolamine or AEA) [8], and 2-Arachido-
noylglycerol (2-AG) [9], have been identified by the Mechoulam 
research group. These seminal studies provided the first complete 
characterization of the endocannabinoid system (ECS). 
 Phytocannabinoids are physiologically produced in plant cell 
substructures called trichomes in the form of resin. From a bio-
chemical point of view, all subclasses of phytocannabinoids origi-
nate from cannabigerol-type (CBG) molecules, according to the 
diverse cyclization products of this precursor Fig. (1). Two possible 
numberings of the C21 phytocannabinoids have been proposed, 
depending on either the dibenzopyran or monoterpenoid scaffold. In 
the present work, we refer to dibenzopyran numbering Fig. (2). 
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Fig. (2). Different numberings of the phytocannabinoid scaffold. 
 
 Some progenitors of the main subclasses of pytocannabinoids 
derived from condensation of olivetolic acid and geranyl pyrophos-
phate are illustrated in Fig. (3). 
 Other classes of pythocannabinoids are derived from the con-
densation of geranyl pyrophosphate (GPP) with divarinolic acid 
instead of olivetolic acid. In the structure of the latter, propyl side 
chains replace the pentyl hydrocarbon residue. These chains include 
tethrahydrocannabivarin (THCV), cannabidivarin (CBDV), can-
nabivarin (CBV), cannabichromevarin (CBCV), and cannabi-
gerovarin (CBGV) [10, 11]. 

9
-THC 
 The compound (6aR,10aR)-delta-9-tetrahydrocannabinol is the 
main psychoactive compound of Cannabis sativa L. and is charac-
terized by a relatively simple structure. Several of this isomer’s 
compounds are known, which vary in their double-bond positions 
(in nature, only 
9
 or 
8
 species are found), cis or trans ring junc-
tions, and absolute stereochemical properties. 
 Four stereoisomers of THC are possible, but only the levorota-
tory ones occur in nature (Table 1). Accordingly, naturally occur-
ring stereoisomers are energetically favored, due to the trans con-
figuration being less strained than the cis configuration. Because of 
its double-bond position, 
9
-THC is thermodynamically less stable 
than 
8
-THC, as indicated by the easy 
9 
–
 

8 
conversion under 
acid treatment. Several efforts have been made to synthesize 
9
-
THC, the main isomer found in Cannabis sativa L. In 1967, Mech-
oulam et al. reported such synthesis from Verbenol and Olivetol 
using acid catalysis [12]; thereafter, many other synthethic proce-
dures were published, including those that started with different 
natural products such as crysanthenol, p-menthadienol, p- 
menthenediol, and carene oxide, resulting in several methods for 
total synthesis [13-16]. 
9
-THC is currently commercialized with 
the INN of dronabinol (brand name Marinol) for medical uses, such 
as stimulating the appetite to prevent anorexia in patients with 
AIDS and as an antiemetic in patients resistant to conventional 
antiemetic treatment for cancer chemotherapy. 
9
-THC is an aro-
matic terpenoid with very low solubility in water but good solubil-
ity in polar organic solvents; as such, it is normally accumulated in 
fatty tissues after prolonged administration.  
Cannabinol (CBN) 
 Cannabinol is a weak psychoactive cannabinoid isolated from 
Cannabis sativa L. and Cannabis indica [17]. It is structurally re-
lated to THC, from which it is obtained biosynthetically by oxida-
tion. CBN differs from THC in that it possesses neither double-
bonded isomers nor stereoisomers. It acts mainly as a weak CB1 
receptor agonist and possesses a higher affinity than THC for CB2 
receptors. It is also the main metabolite of 
9
-THC [18]. 
Cannabidiol (CBD) 
 Cannabidiol is one of the most abundant phytocannabinoids 
isolated from Cannabis sativa L. (up to 40% of the extract) [19]. 
The biosynthesis of CBD starts from a common precursor of THC 
— CBG, which undergoes a C–C one ring cyclization catalyzed by 
cannabidiolic acid (CBDA) synthase — followed by decarboxyla-
tion. Multiple CBD double-bonded isomers and their corresponding 
stereoisomers are possible, but only one isomer is found in nature, 
the one with a double-bond in the same position as 9-THC. Can-
nabidiol is poorly soluble in water but has good solubility in polar 
organic solvents. In the presence of a strong base and oxygen, it is 
oxidized to quinone [20]. It can be converted into THC by acid 
catalyzed cyclization [21]. The synthesis of CBD has been accom-
plished by several research groups [13, 22, 23]. In contrast with 
 
 
 
 
 
 
 
 
 
Fig. (1). The chemical structures of different classes of phytocannabinoids. 
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THC, CBD does not exhibit psychomimetic activities and is capa-
ble of antagonizing these effects. For this reason, CBD has aroused 
increased research interest in its pharmacological properties. Sev-
eral studies show CBD to have anti-inflammatory, anticonvulsant, 
antioxidant, antiemetic, anxiolytic, and antipsychotic properties; 
thus, it may serve as potential drug for the treatment of neuro-
inflammation, epilepsy, oxidative injury, vomiting and nausea, and 
anxiety and schizophrenia, respectively [19]. CBD is commercial-
ized in a 1:1 combination with THC under the trade name Sativex 
for the relief of neuropathic pain in multiple sclerosis. GW pharma-
ceuticals received an Orphan Drug Designation from the Food & 
Drug Administration (FDA) for a purified liquid extract of CBD 
(brand name Epidiolex) in the treatment of Dravet syndrome. The 
drug is currently in phases II and III of clinical trials for Dravet 
syndrome, common epilepsy, schizophrenia, and other rare syn-
dromes. Recently, new evidence of other therapeutic activities of 
CBD has been found in the treatment of cancer and neurodegenera-
tive disorders [24, 25]. 
Endocannabinoids 
 
Fig. (4). The most common endogenous cannabinoids. 
 
 Endogenous cannabinoids, or endocannabinoids, are capable of 
binding to CB receptors; they are lipid-like structures correspond-
ing to those depicted in Fig. (4). Endocannabinoids are obtained 
from arachidonic acid, a common precursor in the biosynthesis of 
prostaglandins, which are key regulators of inflammatory processes. 
These compounds are derived from the non-oxidative metabolism 
of arachidonic acid by formal condensation with ethanolamine or 
glycerol, starting from the precursors eicosanoic phospholipids and 
diacylglycerols, respectively. They are found primarily in the brain 
but are present in almost all human tissues [26]. Thus, endocan-
nabinoids play a biological role in inflammation, insulin sensitivity, 
and fat and energy metabolism. In turn, endocannabinoid inhibitors 
may be precious tools for reducing the prevalence of metabolic 
syndrome. Furthermore, the modulation of the endocannabinoid 
system may display therapeutic potential for diverse chronic neu-
rologic and immune conditions. Anandamide (N-arachidonoyl-
ethanolamine) (AEA) and 2-arachidonoylglycerol (2-AG) are by far 
the most extensively investigated endocannabinoids. 
Synthetic Cannabinoids  
 Since the discovery of natural cannabinoids, novel synthetic 
analogues with similar structures have been prepared by different 
research groups, among which, Mechoulam’s and Huffman’s ones 
are notable examples. Some synthetic THC analogues, such as HU-
210 show activity that is 100-fold higher than THC [27]. The phar-
macological studies on these artificial cannabinoids have elucidated 
structure–activity relationships (SARs) and ECS metabolism [28]. 
Synthetic cannabinoids can be structurally related to THC or can 
have different scaffolds that do and do not contain heterocycle 
rings. Most synthetic cannabinoids are lipid-soluble and apolar, 
consisting of 22–26 carbon atoms. Optimal activity requires more 
than four and up to nine saturated carbon atoms. Big efforts were 
made by John W. Huffman et al., who synthesized more than 450 
artificial cannabinoids. Some of these compounds, which are 
known be their acronyms WIN55212-2, JWH-018, JWH-073, 
JWH-133, and SR141716 (Rimonabant), were shown to be highly 
bioactive; this discovery paved the way for several pharmaceutical 
applications as well as illegal use in smoking mixtures called 
“spice” or “K2.” Synthetic cannabinoids can be classified into 
seven major structural groups: 
• Naphthoylindoles (e.g., JWH-018, JWH-073 and JWH-
398); 
• Naphthylmethylindoles; 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Biosynthetic pathways for some cannabinoids. 
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• Naphthoylpyrroles; 
• Naphthylmethylindenes; 
• Phenylacetylindoles (i.e., benzoylindoles, e.g., JWH-250); 
• Cyclohexylphenols (e.g., CP 47,497 and homologues of CP 
47,497); 
• Classical cannabinoids (e.g., HU-210 and JWH-133). 
 All of these products normally act as agonists or inverse ago-
nists of CB1 and CB2 receptors, and may show alternate selectivity 
towards one of the receptor types. Currently, some of these com-
pounds (WIN55212-2, JWH-133, and HU-210) are under investiga-
tion as potential treatments for Alzheimer’s disease, because they 
show evidence of counteracting the inflammation caused by amy-
loid beta proteins [29]. 
JWH-133 
 JWH-133 is chemically related to THC and is a potent CB2 
selective agonist. This compound was synthesized by John W. 
Huffman’s research group [28]. Its properties against Alzheimer’s 
disease and cancer have also been recently investigated [29, 30]. 
WIN55,212-2 
 WIN55,212-2 is a naphthoylindole derivative (JWH analogue) 
possessing THC-like potent, non-selective, CB receptor agonist 
properties. It has potential therapeutic use as an analgesic and 
against Alzheimer’s disease [29, 31]. 
SR141716 
 Also known as Rimonabant (brand name Acomplia by Sanofi-
Aventis), SR141716 is an inverse selective agonist of the CB1 re-
ceptor [32]. It is a pyrazole derivative and is remarkably easy to 
synthesize [33]. SR141716 was approved as an anorectic in Europe 
for the treatment of obesity, given its efficacy in decreasing appe-
tite. The FDA, however, refused its approval as anti-obesity drug 
because of the severe depression reported as a side effect. 
CANNABINOIDS AND CANCER 
 The cannabinoid receptors CB1 and CB2 comprise the endocan-
nabinoid system (ECS) inside a cell, and the activation of these 
receptors is important for a number of physiological processes that 
regulate nervous, digestive, reproductive, immune, and metabolic 
functions [34]. There is growing body of evidence that the ECS 
system and synthetic cannabinoids modulate the activity of en-
zymes and nuclear factors involved in cancer cell homeostasis, 
growth, migration, metastasis, and tumor angiogenesis [1, 35-38]. 
Remarkably, cannabinoids target cancer cells, while non-tumor 
cells and tissues are avoided. This apparent selectivity for tumor 
cells makes the ECS system an attractive potential target for cancer 
therapy. In 1975, the natural cannabinoid THC was recognized as a 
potential anticancer agent [39], inhibiting lung adenocarcinoma cell 
growth in vitro and in vivo. Since that time, the therapeutic potential 
of cannabinoid for various types of cancer have been widely inves-
tigated [35]. Today, capsules of THC and its synthetic analogues 
have been approved for treating nausea and emesis associated with 
cancer chemotherapy [5].  
 In 2006, the first human clinical study of THC was successfully 
performed in patients with recurrent glioblastoma multiforme [40]. 
The potential palliative effects of cannabinoids as appetite stimula-
tors and pain inhibitors were also confirmed in phase III clinical 
trials in oncology [5, 41]. Now, several plant-derived, synthetic, 
and endogenous cannabinoids that exert an antiproliferation effect 
Table 1. Stereoisomers of 
9
 THC. 
Name IUPAC name Structure 
8-tetrahydrocannabinol 
6a,7,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-
6H-dibenzo[b,d]pyran-1-ol 
O
OH
 
9-tetrahydrocannabinol 
6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-
6H-dibenzo[b,d]pyran-1-ol 
O
OH
 
Naturally occurring stereoisomers 
()-trans-9-tetrahydrocannabinol (6aR,10aR)-9-tetrahydrocannabinol 
O
H
H
OH
 
()-cis-9-tetrahydrocannabinol (6aS,10aR)-9-tetrahydrocannabinol 
O
H
H
OH
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on various cancers are widely recognized [Table 2]. Cannabinoid 
administration has been proven to slow tumor growth, as well as to 
slow lung carcinoma, prostate cancer, glioma, and skin carcinomas 
in mice [39, 42-46]. Importantly, all of these studies found CB1 
receptors, CB2 receptors, or both, which was later confirmed by 
molecular and pharmacological approaches that examined cannabi-
noid-receptor expression and used selective cannabinoid receptor 
agonists (JWH-133 and WIN 55,212-2) and antagonists (such as 
AM-630 and SR-141716A).  
 The binding of cannabinoids to their G-protein-coupled can-
nabinoid receptors affects various cellular pathways, for example, it 
inhibits adenylate cyclase and activates extracellular-signal-
regulated kinase (ERK). This suggests that cannabinoids might also 
be involved in other pathways important for cell survival, such as 
MAPK [47]. The activation of MAPK by cannabinoids has been 
observed in human vascular endothelial cells, neural cell lines, and 
Chinese hamster ovary cells [5, 48, 49]. Both of these kinases 
(MAPK and ERK) are stimulated through G-protein-mediated 
mechanisms [50, 51]. Cannabinoid receptors are also coupled to 
activation of serine/threonine protein kinase B/Akt (PKB), resulting 
in increased phosphorylation of glycogen synthase kinase-3 (GSK3) 
on serine 21 residue [49]. The effect of cannabinoids on sphingo-
myelin breakdown, resulting in increased intracellular ceramide 
levels, has been also observed [52]. Finally, the activation of CB1 or 
CB2 receptors seems to induce apoptosis through de novo synthesis 
of ceramide in various types of cancer cells, including those associ-
ated with glioma, leukemia, colon, and pancreatic cancer [44, 53-
55].  
CANNABINOIDS AS ANTIANGIOGENESIS FACTORS: 
MOLECULAR ASPECTS OF CANNABINOIDS IN CANCER 
PREVENTION 
 The hallmark of cancer is the ability to proliferate despite the 
absence of mitogenic signals. Rapid proliferation of cancer cells 
requires large amounts of energy and oxygen; therefore, hypoxic 
cells secrete proangiogenic factors (e.g., HIF-1a, VEGF, PIGF, 
HGF, and Ang-2 [90-92] to induce the formation of new blood 
vessels to meet their need of increased oxygen. Thus, angiogenesis 
is one of the most important mechanisms through which solid tu-
mors grow rapidly. Currently, more attention is being paid to the 
mechanism of angiogenesis, mostly due to its correlation with can-
cer metastasis, and targeting antiangiogenic molecules has become 
the most promising therapeutic approach to cancer treatment. 
 The range of known antiangiogenic factors is still growing; 
however, most treatment strategies are based on blocking signaling 
from vascular endothelial grow factors (VEGFs), and especially, 
using blocking monoclonal antibodies for VEGFR1 and VEGFR2, 
such as Sunitinib or Bewacizumab [93-95]. Other treatment strate-
gies target various steps in angiogenesis or degrade newly formed 
blood vessels. However, most of these strategies fail due to the 
coexistence of strong proangiogenic factors such as VEGFs and 
EGFs.  
 Cannabinoids have been proven to inhibit angiogenesis in in 
vivo and in vitro studies [38]. Blazquez et al. observed that the local 
administration of JWH-133 altered the blood vessel morphology in 
C6 glioma and grade IV astrocytoma in rats [38]. All tumors treated 
with JWH-133 had a paler overall appearance and only very small 
and narrow capillaries forming differentiated and impermeable 
vascular networks compared to the controls. Moreover, the authors 
showed that cannabinoid administration decreased vascular endo-
thelial cell migration, survival, and expression of major proangio-
genic factors such as VEGF, Ang-2, and MMP2 proteins [38]. 
 Analysis of microarray data showed that JWH-133 administra-
tion in C6 glioma-bearing mice induced altered expression of 10 
genes directly or indirectly related to the VEGF pathway. The can-
nabinoid treatment decreased the expression of VEGF itself, HIF-
1a, heme oxygenase-1, Id3, midkine, angiopoietin-2, and Tie-1 
[96]. Cannabinoids WIN-55,212-2 and JWH-133 also decreased the 
expression of phosphorylated VEGFR-2 in the tumors of two 
glioma patients. The sphingolipid messenger ceramide might be 
responsible for cannabinoid-induced inhibition of VEGF and 
VEGFR2 protein expression. The same compounds were also effi-
cient in the treatment of non-melanoma skin cancer by decreasing 
new blood vessel formation [46, 97].  
 Matrix metalloproteinases (MMPs) are other possible molecular 
targets for cannabinoid treatment [98]. MMPs belong to the family 
of enzymes that participate in the degradation of the vascular base-
ment membrane and remodeling of the extracellular matrix (ECM) 
[99]. This process sends one of the signals required for endothelial 
cells to migrate and form new blood vessels. MMPs have been 
linked to tumor invasion and their increased expression is found in 
almost every type of cancer [100, 101]. Blazquez et al. investigated 
the role of cannabinoid agonists (THC, JWH-133, and anadamide) 
on MMP-2 expression inside glioma cell cultures and glioma-
bearing mice [98], and found that THC administration decreased 
tumor growth and the expression of MMP-2 in C6.9 glioma cells. 
The MMP-2 level also decreased in biopsies obtained from patients 
with recurrent glioblastoma multiform after local administration of 
THC. However, the study also demonstrated the selective nature of 
THC because the level of other MMP protein family members 
(MMP-3, MMP-9, and MMP-14) remained unchanged Fig. (5) 
[98].  
CANNABINOIDS AND THE TUMOR MICROENVIRON-
MENT  
 Interactions between the various cell types observed within a 
tumor mass influence its development, progression, and metastasis. 
The composition of the microenvironment and roles of particular 
cells vary, depending on the tumor type and organ of origin. These 
cells contribute to tumor development by secreting various pro-
tumor factors or by inducing immunosuppression. One of the most 
important cell types to facilitate tumor development is tumor-
associated macrophages (TAMs) [102-104]. TAMs are recruited 
into a tumor mass by various cytokines and chemokines secreted by 
cancer cells. Once they migrate to the tumor, they start to secrete 
various proangiogenic factors or enzymes that facilitate matrix 
remodeling. On the other hand, cancer cells influenced by macro-
phages start to express genes and antigens that are atypical (but 
specific to macrophages, such as chemokines CCL5 and CSF-1 and 
their receptors CXCR5 and CSF-1R) [105, 106]. Indeed, chemoat-
tractants secreted by cancer cells that increase the migratory abili-
ties of immune cells and their infiltration to a tumor mass can also 
enhance cancer cell migration in an autocrine manner. Due to the 
involvement of TAMs in cancer development, inhibition of their 
migration into a tumor mass has been proposed as one therapeutic 
approach [102]. 
 There are no published papers about the influence of cannabi-
noids on the tumor microenvironment and TAMs. However, the 
expression level of CB2 receptors is considerably upregulated in 
activated macrophages [107]. CB2 receptors control several func-
tions of macrophages, such as actin polymerization, migration, cell 
phenotype, and cytokine release from these cells [107]. Cannabi-
noid ligands share receptors with important chemotactic cytokines 
that direct the migration of immune cells. These receptors are cou-
pled to heterotrimeric Gi proteins [108]. Ghosh et al. reported that 
the CB1/CB2 agonist CP55940, and CB2-selective agonist JW-015, 
caused significant inhibition of chemokine CXCL12-induced che-
motaxis of T lymphocytes [109]. Raborn et al. demonstrated that 
THC and cannabinoids that activate the CB2 inhibit macrophage 
chemotaxis to CCL5 [108]. Because CCL5 is a very important 
ligand for G protein-coupled receptors CCR1 and CCR5, activation 
of the CB2 leads to trans-deactivation of these receptors, which play 
specialized roles in leukocyte trafficking [110-112].  
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 These results indicate that cannabinoids and chemokines may 
constitute integrative components of a network of intercommunicat-
ing G protein-coupled receptors that not only regulate the immune 
responses and chemokine/cytokine-regulated chemotaxis of leuko-
cytes but also the migration of cancer cells. Addition-
ally,cannabinoids, as highly lipophilic molecules, can perturb cellu-
lar membranes and alter ligand–receptor interaction, disrupt recep-
tor-G protein complexes, and alter the cascade of signal transduc-
tion, thus decreasing the migratory abilities of cells [113-115].  
 The cannabinoid-based inhibition of immune cell migration to a 
tumor mass (in particular macrophages), or the alteration of 
chemokine/cytokine signaling in cancer cells, may constitute a 
beneficial approach in anticancer therapy. Therefore, the regulatory 
function of cannabinoids on the tumor microenvironment needs 
further investigation. 
CANNABINOIDS IN ANTICANCER THERAPY FOR RE-
NAL CELL CARCINOMA 
 Renal cell carcinoma (RCC) represents a serious problem in 
oncology — it is the cause of over 100,000 deaths each year. RCC 
is the most common type of renal cell tumor, consisting of a sub-
stantial number of malignant cancers and benign tumors. This type 
of cancer has a higher risk of appearance in males [116]. The treat-
ment of choice for renal cancers are nephrectomy combined with 
Table 2. The cannabinoid modulation of different cancers and pathways.  
Cancer Type Signaling Pathways 
Involved 
Effects Experimental 
System 
Receptors 
Involved 
Cannabinoids Tested References 
Glioma ERK, 
MAPK, cAMP, 
LOX, PI3K/Akt/mTOR 
Decrease tumor vol-
ume and apoptosis 
In vitro 
In vivo (rat, 
mouse) 
CB1, CB2 THC, 
WIN55,212-2, JWH-133, 
AM-1241, CBD, SR144528, 
SR141716 
[44, 56-62] 
 
 
Breast NF-B, PA-1, cAMP, 
PKA, 
MAPK, S1P/ceramide, 
CXCR4/CXCL12 
Cell cycle arrest, 
Apoptosis and inhibit 
tumor growth 
In vitro 
In vivo (mouse) 
CB1, CB2 AEA, THC, CBD, 
WIN55,212-2, 
JWH-015,  
SR 141716A 
[63-68] 
Lung MAPKs, 
PI3K/Akt/mTOR, JNK, 
ERK 
Decrease tumor 
growth, invade cancer 
cells, and induce 
apoptosis 
In vitro 
In vivo (mouse) 
CB1, CB2 THC, CBN, CBD, 
AM-251, 
AM-630 
[39, 69-72] 
Leukemia cAMP, ECS Decrease tumor 
growth, apoptosis 
In vitro 
In vivo (mouse) 
CB2 THC, JWH-015, SR144528 [73-75] 
Melanoma COX-2, LOX, Akt Apoptosis, inhibit 
cancer cell growth 
In vitro 
In vivo (mouse) 
CB1, CB2 JWH-133, WIN55,212-2, 
AM251, AEA, AM251, 
SR141716, SR144528 
[46, 76, 77] 
 
 
 
Prostate NF-B/cyclin D/cyclin 
E, JNK, Akt 
Arrest cell cycle, 
apoptosis, and de-
crease tumor volume 
In vitro 
In vivo 
(mouse) 
CB1, CB2 AEA, JWH-015, WIN55,212-
2,  
SR 144528, SR141716A 
[37, 78-81] 
 
Thyroid cAMP, ERK, MAPK Decrease tumor vol-
ume, apoptosis 
In vitro 
In vivo 
(mouse) 
CB1, CB2 AEA, JWH133, 
SR141716A 
[82-84] 
Pancreatic (Ca2+) Calcium signal-
ing, p8-ATF-4-TRB3 
Inhibit cancer cells, 
reduce tumor growth 
In vitro 
(mouse) 
CB1, CB2 ACPA, GW,  
WIN 55,212-2, SR141716, 
SR144528 
[55, 85] 
 
Kidney ? ? In vitro CB1? CB2? ? [36, 86] 
Ovary ? ? In vivo 
(mouse) 
CB1, CB2 ? [87] 
Bladder (Ca2+) Calcium signal-
ing 
Decrease cancer cell 
proliferation by delay-
ing the cell cycle 
progression 
In vitro 
 
CB1, CB2 2-AG, AEA, AM-281, 
CP55,940 
[88, 89] 
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immunotherapy [117], due to the high costs of other therapies or 
late detection. However, novel drugs give hope to cancer patients 
— for example, therapies concerning the tyrosine kinase receptor 
inhibitor or multipurpose drugs targeting not only cancer cells but 
also stimulating the immune response. However, there is no perfect 
therapy for eliminating tumor cells. Investigation of the anticancer 
properties of natural compounds, such as cannabinoids, have 
brought interesting results. 
 Medical cannabis still remains a prescribed medication in some 
of therapeutic protocols and Cannabis sativa L. has started to be-
come one of the most commonly used additional medications to 
treat nausea (caused, for example, by chemotherapy), stimulate the 
appetite, and deal with chronic pain [5, 118].
 Cannabinoids also have an important influence on cancer cells 
themselves, what was mentioned before in this manuscript. There 
are many ways they inhibit tumor proliferation and survival. Fig. 
(6) illustrates a couple of ways CB1 and CB2 receptors are inte-

Fig. (5). The influence of CB1 and CB2 activity on angiogenesis in cancer: After binding to a specific agonist, both CB1 and CB2 receptors are activated. This 
leads to direct and indirect changes that have crucial effects on angiogenesis in a cancerous environment. Inactivation of the PI3K/Akt pathway leads to lower 
HIF-1 and VEGF levels — two of the most known proangiogenic molecules. CB1 receptor activation leads to the direct inhibition of VEGF type 2 receptors, 
which are major angiogenesis inducers. When activated, CB1 and CB2 receptors strictly inhibit adenylyl cyclase (AC). PKAs, whose activity is strictly depend-
ent on the cellular levels of cAMP, are inactivated and unable to phosphorylate CREB/ATF, decreasing nitric oxide synthase (NOS). Ras inactivation leads to 
inactivation of the whole pathway, including ERK and MAPK. Metalloproteinases production is stopped by the activation of both cannabinoid type 1 and type 
2 receptors. Thus, all of these events have a direct impact on angiogenesis as well as the cell cycle and proliferation. 
 
Fig. (6). ECS system-related pathways: The activation of CB1/CB2 receptors has an immense effect on the fate of cells, leading them to apoptosis. Adenylyl 
cyclase is inhibited by the activation of both cannabinoid type 1 and type 2 receptors. Inhibiting various pathways — including the PI3K/Akt pathway and 
cAMP-dependent PKA and Ras phosphorylation — results in stimulating cell death through numerous secreted molecules, such as Bad, Bcl2, and Fos. Secret-
ing apoptotic proteins, such as p27 and p21 via ceramide synthesis, speeds up the process of apoptosis. 
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grated into intracellular pathways. However, all of mechanisms are 
not identical in every cell and do not occur simultaneously.  
 In the case of RCC, research is still lacking on cannabinoids as 
anticancer compounds. However, the expression of cannabinoid 
receptors (CB1, CB2, TRPV1, and GPR55) in kidney cells and RCC 
has been confirmed [119]. The expression of cannabinoid receptors 
CB1 and CB2 was first confirmed in the human proximal tubule 
(HK2) cell line, and also lysate from rat kidney [145]. Larrinaga et 
al. investigated the expression of cannabinoid receptors in human 
fetal and adult kidneys [120], finding that CB1 (CNR1a) mRNA 
was present in all samples; however, CB2 (CNR2) mRNA was un-
detectable in all samples. Further studies are needed to help clarify 
these differences and the role of ECS in renal function. 
 Renal cell carcinoma (RCC) is the most common epithelial 
malignancy of the kidney in adults, accounting for 3% of all neo-
plasms [121]. Considering the specific cannabinoid receptors in 
kidneys, as well as the pro-apoptotic, antiproliferative, anti-metas-
tatic and antiangiogenic effects of cannabinoids, this field should be 
explored. So far, there are only a few published papers about the 
ECS in RCC.  
 Some results also suggest that patterns of cannabinoid receptor 
expression could be used in differential diagnosis of kidney can-
cers. Chromophobe RCC (ChRCC) and renal oncocytoma (RO) are 
two histologically distinct neoplastic entities of renal tumors. These 
tumors originate from distinct sites in the kidney and show different 
molecular abnormalities. In ChRCC samples, the mRNA expression 
for CB1 receptors was 12-fold lower than in the surrounding normal 
tissue [86]. However, RO samples showed no difference in the level 
of CB1 mRNA expression between the tumor and surrounding tis-
sue. The mRNA expression for CB2 receptor was undetectable in 
both ChRCC and RO. Interestingly, protein expression analysis of 
these RCC neoplasms failed to provide any evidence for the expres-
sion of CB1 [36, 86]. Thus, the CB1 protein may undergo modifica-
tions in these tumors at the post-transcriptional level. Therefore, 
further studies are required to understand the role of cannabinoids 
and their receptors in RCC. 
CONCLUSION 
 More research is needed to answer all questions about the po-
tential use of cannabinoids to treat cancer. The first question is 
which type of cannabinoids should be used to treat cancer patients 
— natural or synthetic? Different cannabinoids seem to have differ-
ent effects on various cancer types, which may be caused by the 
different expression of cannabinoid receptors in various cancer 
types. Similarly, no studies have shown the effects of cannabinoids 
on the efficacy of chemotherapy. The psychoactive effect of can-
nabinoids should also be considered before its routine use. 
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LIST OF ABBREVIATIONS 
2-AG = 2-arachidonoylglycerol,  
ACPA = arachidonylcyclopropylamide  
AM-630 = 6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-
1H-indol-3-yl](4-methoxyphenyl)methanone 
Ang2 = angiopoietin-2 
cAMP = cyclic adenosine monophosphate 
CB1 = Cannabinoid receptor type 1 
CB2 = Cannabinoid receptor type 2 
CBD = Cannabidiol 
CBDA = Cannabidiolic-acid 
CBN = Cannabinol 
CCL5 = CC chemokine ligand-5 
CCR1 = CC chemokine receptor 1 
CCR5 = CC chemokine receptor 5 
ChRCC = Chromophobe RCC 
CP55,940 = (-)-cis-3-[2-Hydroxy-4-(1,1-
dimethylheptyl)phenyl]-trans-4-(3-
hydroxypropyl)cyclohexanol 
CSF-1 = colony stimulating factor-1 
CXCR5 = C-X-C chemokine receptor type-5 
ECM = extracellular matrix 
ECS = endocannabinoid system 
ERK = extracellular-signal-regulated kinase 
GSK3 = glycogen synthase kinase-3 
GW = 1-(2,3-dichlorobenzoyl)-2-methyl-3-(2-(1-
morpholine)ethyl)-5-methoxyindole 
HGF = hepatocyte growth factor 
HIF- = hypoxia-inducible factor-1 alpha 
JNK = c-Jun-NH2-kinase 
JWH-133 = (6aR,10aR)-3-(1,1-dimethylbutyl)-
6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-
dibenzo[b,d]pyran 
MAPKs = mitogen-activated protein kinases  
MMPs = matrix metalloproteinases 
NOS = nitric oxide synthase 
PIGF = placenta growth factor 
PKB = serine/threonine protein kinase B/Akt 
RCC = renal cell carcinoma 
RO = renal oncocytoma 
SAR = Structure-activity relationships 
SR141716 = 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-
methyl-N-1-piperidinyl-1H-pyrazole-3-
carboxamide 
TAM = tumor-associated macrophage 
THC = 
9
tetrahydrocannabinol 
TNF- = tumor necrosis factor alpha 
VEGF = vascular endothelial growth factor 
VEGFR1 = vascular endothelial growth factor receptor 1 
VEGFR2 = vascular endothelial growth factor receptor 2 
WIN-55,212-2 = (R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-
benzoxazin-6-yl]-1-naphthalenylmethanone 
mesylate 
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